Business
Press Release Nov 04 2021
Lupin Limited has informed the Exchange regarding a press release dated November 04, 2021, titled "Lupin s Namuscla�� (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders".
About this update from Lupin Limited
[{"type":"text","content":" Lupin Limited has informed the Exchange regarding a press release dated November 04, 2021, titled \"Lupin s Namuscla�� (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders\". View Attachment","length":410,"tagName":"div"}]